InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: None

Tuesday, 01/16/2018 10:04:17 AM

Tuesday, January 16, 2018 10:04:17 AM

Post# of 48316
Merck hitting it out of the ballpark today in NSCLC. Good PISCES data in 2018 for Oncosec could also lead to a combo study with Merck in NSCLC. That would be a huge opportunity for both companies in the anti-pd1 failure population.